Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1

Maria Elisa Perico, Delia Mezzanzanica, Elena Luison, Paola Alberti, Luigi Panza, Giovanni Russo, Silvana Canevari

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aberrant glycosylation is one of the most constant traits of malignant cells. The CaMBr1 hexasaccharide antigen, originally defined on the human breast carcinoma cell line MCF7, is expressed on some normal tissues but overexpressed in a high percentage of human breast, ovary, prostate and lung carcinomas. CaMBr1 overexpression is associated with poor prognosis. The epitope consists of the tetrasaccharide Fuc(α1-2)Gal(β1-3)GalNAc(β1-3)Galα-O-spacer, which has recently become available as a synthetic oligosaccharide. Here we report the CaMBr1 tetrasaccharide conjugation to two different carrier proteins (CRM197 and KLH) and the evaluation of conjugate immunogenicity in mice following their administration in various vaccine formulations with two adjuvants (MPL-SE and Detox-PC). Radioimmunoassay to determine the level and isotype of anti-tetrasaccharide antibodies in mouse sera, and cytofluorimetric analysis and 51Cr-release assay on human tumor cells, to evaluate specificity of binding and complement-dependent lysis respectively, identified CaMBr1-CRM197, in association with the MPL-SE adjuvant, as the best vaccine formulation. This combination induced (1) production of tetrasaccharide-specific antibodies, with negligible side-effects; (2) antibodies with complement-mediated cytotoxic activity on human CaMBr1-positive cells and (3) a high titer of IgG1 detected in sera obtained 3 months after the first injection, indicating that the anti-tetrasaccharide antibody response was mediated by T cell activation. The availability of CaMBr1-glycoconjugate in the minimal and functional antigenic structure and the identification of an efficacious vaccine formulation opens the way to exploring the activity of this glycoconjugate in a clinical setting.

Original languageEnglish
Pages (from-to)296-304
Number of pages9
JournalCancer Immunology, Immunotherapy
Volume49
Issue number6
Publication statusPublished - 2000

Fingerprint

Neoplasm Antigens
Glycoconjugates
Vaccines
Anti-Idiotypic Antibodies
Antibodies
Serum
Oligosaccharides
Glycosylation
Human Activities
Antibody Formation
Radioimmunoassay
Prostate
Epitopes
Ovary
Carrier Proteins
Breast
Immunoglobulin G
Breast Neoplasms
Carcinoma
T-Lymphocytes

Keywords

  • Glycoconjugates
  • Immunogenicity
  • Tumor-associated-antigen
  • Vaccine formulation

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1. / Perico, Maria Elisa; Mezzanzanica, Delia; Luison, Elena; Alberti, Paola; Panza, Luigi; Russo, Giovanni; Canevari, Silvana.

In: Cancer Immunology, Immunotherapy, Vol. 49, No. 6, 2000, p. 296-304.

Research output: Contribution to journalArticle

Perico, ME, Mezzanzanica, D, Luison, E, Alberti, P, Panza, L, Russo, G & Canevari, S 2000, 'Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1', Cancer Immunology, Immunotherapy, vol. 49, no. 6, pp. 296-304.
Perico, Maria Elisa ; Mezzanzanica, Delia ; Luison, Elena ; Alberti, Paola ; Panza, Luigi ; Russo, Giovanni ; Canevari, Silvana. / Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1. In: Cancer Immunology, Immunotherapy. 2000 ; Vol. 49, No. 6. pp. 296-304.
@article{18c72c4fda6741fc840bb977f0fbd11f,
title = "Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1",
abstract = "Aberrant glycosylation is one of the most constant traits of malignant cells. The CaMBr1 hexasaccharide antigen, originally defined on the human breast carcinoma cell line MCF7, is expressed on some normal tissues but overexpressed in a high percentage of human breast, ovary, prostate and lung carcinomas. CaMBr1 overexpression is associated with poor prognosis. The epitope consists of the tetrasaccharide Fuc(α1-2)Gal(β1-3)GalNAc(β1-3)Galα-O-spacer, which has recently become available as a synthetic oligosaccharide. Here we report the CaMBr1 tetrasaccharide conjugation to two different carrier proteins (CRM197 and KLH) and the evaluation of conjugate immunogenicity in mice following their administration in various vaccine formulations with two adjuvants (MPL-SE and Detox-PC). Radioimmunoassay to determine the level and isotype of anti-tetrasaccharide antibodies in mouse sera, and cytofluorimetric analysis and 51Cr-release assay on human tumor cells, to evaluate specificity of binding and complement-dependent lysis respectively, identified CaMBr1-CRM197, in association with the MPL-SE adjuvant, as the best vaccine formulation. This combination induced (1) production of tetrasaccharide-specific antibodies, with negligible side-effects; (2) antibodies with complement-mediated cytotoxic activity on human CaMBr1-positive cells and (3) a high titer of IgG1 detected in sera obtained 3 months after the first injection, indicating that the anti-tetrasaccharide antibody response was mediated by T cell activation. The availability of CaMBr1-glycoconjugate in the minimal and functional antigenic structure and the identification of an efficacious vaccine formulation opens the way to exploring the activity of this glycoconjugate in a clinical setting.",
keywords = "Glycoconjugates, Immunogenicity, Tumor-associated-antigen, Vaccine formulation",
author = "Perico, {Maria Elisa} and Delia Mezzanzanica and Elena Luison and Paola Alberti and Luigi Panza and Giovanni Russo and Silvana Canevari",
year = "2000",
language = "English",
volume = "49",
pages = "296--304",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "6",

}

TY - JOUR

T1 - Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1

AU - Perico, Maria Elisa

AU - Mezzanzanica, Delia

AU - Luison, Elena

AU - Alberti, Paola

AU - Panza, Luigi

AU - Russo, Giovanni

AU - Canevari, Silvana

PY - 2000

Y1 - 2000

N2 - Aberrant glycosylation is one of the most constant traits of malignant cells. The CaMBr1 hexasaccharide antigen, originally defined on the human breast carcinoma cell line MCF7, is expressed on some normal tissues but overexpressed in a high percentage of human breast, ovary, prostate and lung carcinomas. CaMBr1 overexpression is associated with poor prognosis. The epitope consists of the tetrasaccharide Fuc(α1-2)Gal(β1-3)GalNAc(β1-3)Galα-O-spacer, which has recently become available as a synthetic oligosaccharide. Here we report the CaMBr1 tetrasaccharide conjugation to two different carrier proteins (CRM197 and KLH) and the evaluation of conjugate immunogenicity in mice following their administration in various vaccine formulations with two adjuvants (MPL-SE and Detox-PC). Radioimmunoassay to determine the level and isotype of anti-tetrasaccharide antibodies in mouse sera, and cytofluorimetric analysis and 51Cr-release assay on human tumor cells, to evaluate specificity of binding and complement-dependent lysis respectively, identified CaMBr1-CRM197, in association with the MPL-SE adjuvant, as the best vaccine formulation. This combination induced (1) production of tetrasaccharide-specific antibodies, with negligible side-effects; (2) antibodies with complement-mediated cytotoxic activity on human CaMBr1-positive cells and (3) a high titer of IgG1 detected in sera obtained 3 months after the first injection, indicating that the anti-tetrasaccharide antibody response was mediated by T cell activation. The availability of CaMBr1-glycoconjugate in the minimal and functional antigenic structure and the identification of an efficacious vaccine formulation opens the way to exploring the activity of this glycoconjugate in a clinical setting.

AB - Aberrant glycosylation is one of the most constant traits of malignant cells. The CaMBr1 hexasaccharide antigen, originally defined on the human breast carcinoma cell line MCF7, is expressed on some normal tissues but overexpressed in a high percentage of human breast, ovary, prostate and lung carcinomas. CaMBr1 overexpression is associated with poor prognosis. The epitope consists of the tetrasaccharide Fuc(α1-2)Gal(β1-3)GalNAc(β1-3)Galα-O-spacer, which has recently become available as a synthetic oligosaccharide. Here we report the CaMBr1 tetrasaccharide conjugation to two different carrier proteins (CRM197 and KLH) and the evaluation of conjugate immunogenicity in mice following their administration in various vaccine formulations with two adjuvants (MPL-SE and Detox-PC). Radioimmunoassay to determine the level and isotype of anti-tetrasaccharide antibodies in mouse sera, and cytofluorimetric analysis and 51Cr-release assay on human tumor cells, to evaluate specificity of binding and complement-dependent lysis respectively, identified CaMBr1-CRM197, in association with the MPL-SE adjuvant, as the best vaccine formulation. This combination induced (1) production of tetrasaccharide-specific antibodies, with negligible side-effects; (2) antibodies with complement-mediated cytotoxic activity on human CaMBr1-positive cells and (3) a high titer of IgG1 detected in sera obtained 3 months after the first injection, indicating that the anti-tetrasaccharide antibody response was mediated by T cell activation. The availability of CaMBr1-glycoconjugate in the minimal and functional antigenic structure and the identification of an efficacious vaccine formulation opens the way to exploring the activity of this glycoconjugate in a clinical setting.

KW - Glycoconjugates

KW - Immunogenicity

KW - Tumor-associated-antigen

KW - Vaccine formulation

UR - http://www.scopus.com/inward/record.url?scp=0033855365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033855365&partnerID=8YFLogxK

M3 - Article

C2 - 10946811

AN - SCOPUS:0033855365

VL - 49

SP - 296

EP - 304

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 6

ER -